LOW-GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW-GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW-GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW-GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody combo aims to fight back against recurrent ovarian cancer
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the drugs can shrink tumors or control the cancer. Researchers will also monitor side…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC